CD274 and neoplasm: Taken together, these results indicate that this novel PD-L1-containing MUC1-Vax-DC vaccine can inhibit the growth of MUC1+ and PD-L1+ tumor cells, and may be an effective therapeutic vaccine against MUC1+ and PD-L1+ tumors.